First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Hikma Pharmaceuticals: the story is balanced — US FDA approval pipeline and timing of generic launches (particularly complex injectables with limited competition)
★ Analysts see FY2027 revenue reaching $3.6B — +4.8% growth in a single year.
What Moves the Stock
1US FDA approval pipeline and timing of generic launches (particularly complex injectables with limited competition)
2Pricing dynamics in US generics market - GPO contract renewals and competitive intensity in key molecules
3MENA region pharmaceutical demand growth (7-9% CAGR driven by population growth, chronic disease prevalence, healthcare infrastructure investment)
4Currency fluctuations - Egyptian pound, Algerian dinar, Saudi riyal exposure (30-35% of revenue in local currencies)
5Regulatory actions - FDA warning letters, import alerts, or facility approvals affecting manufacturing capacity
6Generics segment (~45-50% of revenue): US injectable generics including oncology, anesthesia, and critical care products sold to hospitals and GPOs
7Branded segment (~30-35% of revenue): Proprietary formulations for chronic conditions (diabetes, cardiovascular, respiratory) sold across MENA region through direct sales force
8Injectables segment (~20-25% of revenue): Specialty hospital injectables and biosimilars distributed globally, particularly in Europe and emerging markets
value - Stock trades at 11.1x EV/EBITDA vs peer group average 13-15x despite 8.8% revenue growth and 15.4% ROE.
Rising rates create moderate headwind through higher financing costs on $750M net debt position (estimated 200-250bps impact on interest…
Watch on earnings: US FDA approval rate and ANDA pipeline (target 15-20 approvals annually, current backlog estimated 40-50 pending), MENA healthcare expenditure as % of GDP (currently 4-6% across key markets, target 8-10% by 2030), Generic drug price index (CPI pharmaceutical component) - tracks industry-wide pricing pressure.
One Sentence Summary:
Hikma Pharmaceuticals: the story is balanced — us fda approval pipeline and timing of generic launches (particularly complex injectables with limited competition).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.